drugset / Trial / NCT03927573
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
Phase 1
Terminated
23 enrolled
AvenCell Europe GmbH
GCP-Service International Ltd. & Co. KG · collab
NaSequentialOpen-labelTreatment
Summary
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to respond to standard therapy.
Timeline
- Start
- 2019-04-15
- Primary completion
- 2023-06-28
- Completion
- 2023-06-28
Outcome
Outcome not reported
Stopped (Business): “business decision by sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEM3PSCA | Unknown | — | Intravenous |